Women Have Been Left Out of Medical Research, and the Consequences Are Still Here

For most of modern medicine, the female body was treated as too complicated to study. The result is a women's health research gap that still shapes diagnosis and treatment today. Until 1993, the default research subject in most clinical trials was a seventy kilogram male. It sounds dramatic. It isn't. A medication that works one way in men can work very differently in women. A heart attack can look like nausea, jaw pain, or fatigue instead of the version everyone was taught to recognise. A woman can spend years being told her symptoms are stress, ageing, or anxiety when the real problem was never properly studied in the first place.

What the Women's Health Research Gap Means for Women Today

This gap is particularly significant for women navigating perimenopause, where the research base for symptoms like brain fog, mood changes, and hormonal shifts remains underdeveloped.

To understand why these symptoms are so often misunderstood, it helps to look at what biological aging means for women.

The consequences of studying only men

Ambien is one example. For years, women were given the same dose as men, even though they metabolised it differently and were more likely to still have enough of the drug in their system the next morning.

That kind of gap is not minor. It is the difference between a treatment that fits the body it was designed for and one that does not.

What the data gap still means today

The problem goes beyond medication. For conditions like endometriosis, chronic fatigue, migraines, and the mood and cognitive symptoms of perimenopause, the issue is often not just that women are dismissed. It is that the research base is still thin enough that clear diagnostic criteria, reliable biomarkers, and evidence-based treatment options are missing or incomplete.

What changes it

That is what decades of exclusion looks like. Not just fewer answers, but weaker definitions of what is even being looked for.

The female body is not a variant. It is half the population. The sooner research treats it as the default, not the exception, the sooner medicine catches up.

Join Vital Edit in Berlin for evidence-based conversations, new connections with inspiring women, and learning without sales pitches.